Market's view on Physiomics
Published on April 2024
- One stock watcher critiqued the claim that a stable share price indicates good performance, highlighting a scenario where the share price dropped after the announcement of new contracts and revenues.
- Praise was noted for a company’s ongoing relationship with a big pharma client, which led to additional business, suggesting a positive outlook for future dealings.
- A significant contract, valued at over 10% of the market capitalisation for a six-month period, was highlighted as very positive news, indicating solid potential growth and a positive impact on the share price.
- It was mentioned that the market capitalisation of the company stands at a modest £1.6 million.
- Concerns were raised about the company’s long-standing history of losses, with expectations set for continued similar performance despite past outcomes.
- Positive remarks were made about the company’s communication with shareholders and its handling of investor relations compared to another firm, suggesting good governance and shareholder respect.